Vanguard Group
SKYE icon

Vanguard Group’s Skye Bioscience SKYE Stock Holding History

Vanguard Group’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$662K Hold
882,785
– – ﹤0.01% 3879
2025
Q3 		$3.47M Buy
882,785
+44,824
+5% +$169K ﹤0.01% 3400
2025
Q2 		$3.5M Sell
837,961
-115,411
-12% -$239K ﹤0.01% 3326
2025
Q1 		$1.52M Buy
953,372
+92,545
+11% +$253K ﹤0.01% 3579
2024
Q4 		$2.44M Buy
860,827
+16,654
+2% +$69.6K ﹤0.01% 3500
2024
Q3 		$3.3M Buy
844,173
+10,553
+1% +$59.2K ﹤0.01% 3412
2024
Q2 		$6.68M Buy
+833,620
New +$9.89M ﹤0.01% 3119

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group's SKYE Position: Q4 2025 in Review

Vanguard Group held its Skye Bioscience (SKYE) position steady in Q4 2025 at 882,785 shares worth $662K. The position accounts for ﹤0.01% of the portfolio, ranked #3879.

Vanguard Group first reported a position in SKYE in Q2 2024 and has held it in 7 quarters since. The position peaked at $6.68M in Q2 2024. 50 funds tracked by Wall St. Rank hold SKYE as of Q4 2025.

  • Vanguard Group held 882,785 shares of Skye Bioscience worth $662K as of Q4 2025.
  • Vanguard Group left its Skye Bioscience share count unchanged in Q4 2025.
  • Skye Bioscience made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3879 holding.
  • Vanguard Group first reported a position in Skye Bioscience in Q2 2024 and has held it in 7 quarters since.
  • Vanguard Group's Skye Bioscience position peaked at $6.68M in Q2 2024.
  • 50 funds tracked by Wall St. Rank held Skye Bioscience as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.